A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASE

Alexandra Marine and General Hospital21 enrolled

Overview

The purpose of this study is to assess the ability of CJH1 to increase the sensitivity of dopamine receptors and thereby reduce symptoms of Parkinson's Disease.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Parkinson's Disease

Interventions

CJH1 (CLR4001)DRUG

Eligibility

Sex: ALLMin age: 40 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient's with Parkinson's disease Exclusion Criteria: * Contraindications to study medication

Locations (1)

Gateway Rural Health Research

Goderich, Ontario, Canada

RECRUITING

Outcomes

Primary Outcomes

Reduced signs and symptoms of Parkinson's disease

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.